Advances in liquid biopsy approaches for early detection and monitoring of cancer
Open accessAbstract
Progress in sensitive analytical approaches has opened new avenues for the detection of cells or products such as circulating cell-free DNA released by tumors. These 'liquid biopsies' are being explored in clinical trials for early cancer detection, prediction of recurrent disease, and assessment of therapeutic resistance mechanisms.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In NGS, liquid biopsies from cfDNA in body fluids are of great interest for identifying chromosomal or other genetic mutations to diagnose malignancies in presymptomatic phase.
“In the next-generation sequencing (NGS) field, there is great interest in the use of liquid biopsies from cell-free DNA (cfDNA) extracted from body fluids, such as plasma, to identify chromosomal or other genetic mutations and thus diagnose malignancies in the presymptomatic phase123.”
From Clinical metagenomics (2019) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783 · see citing works
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal‐Hanjani, M., Constantin, T. P., Salari, R., Quesne, J. P. C. L., Moore, D. A., Veeriah, S., Rosenthal, R., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,880 · see citing works
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492 · see citing works
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,091 · see citing works
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,079 · see citing works
Circulating tumour cells in cancer patients: challenges and perspectives
Pantel, K., & Alix‐Panabières, C. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.001 · Cited by 816 · see citing works
Self-citationLiquid Biopsies, What We Do Not Know (Yet)
Bardelli, A., & Pantel, K. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.002 · Cited by 482 · see citing works
Self-citationCirculating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
GOODALL, J. C., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Pérez-López, R., Dolling, D. I., Robinson, D. R., Sandhu, S. K., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0261 · Cited by 421 · see citing works
Goh, J. Y., Feng, M., Wang, W., Oguz, G., Yatim, S. M. J. M., Lee, P. L., Bao, Y., Lim, T. H., Wang, P., Tam, W. L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4405 · Cited by 158 · see citing works
Berghuis, A., Koffijberg, H., Prakash, J., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020363 · Cited by 49 · see citing works
Cell-Free DNA in Oncology: Gearing up for Clinic
Ulrich, B. C., & Paweletz, C. P. (2017) · Annals of Laboratory Medicine · doi:10.3343/alm.2018.38.1.1 · Cited by 45 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Chiu, C. Y., & Miller, S. A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0113-7 · Cited by 1,620 · see citing works
Ramirez-Garrastacho, M., Bajo-Santos, C., Line, A., Martens-Uzunova, E. S., de la Fuente, J. M., Moros, M., Soekmadji, C., Tasken, K. A., & Llorente, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01610-8 · Cited by 130 · see citing works
- Authors
- Babayan, A., & Pantel, K.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Corresponding author
- Babayan, Anna
- Pantel, Klaus
- Venue
- Genome Medicine
- Published
- 2018-03-20
- Volume
- 10
- Issue
- 1
- Pages
- 21-21
- ISSN
- 1756-994X (ISSN-L)
- PMC
- PMC5861602
- OpenAlex
- W2806488417
- Cited by
- 104
- References
- 11
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 19 · 2020: 18 · 2019: 22 · 2018: 10
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Genome Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
- Keywords
- liquid biopsy, cell-free DNA, early cancer detection, tumor recurrence prediction, treatment resistance, cancer monitoring
- MeSH terms
- Liquid Biopsy, Humans, Neoplasm Staging, Neoplasms, Neoplasm, Residual, Early Detection of Cancer, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
